GlassScriptPhysician profile
Ayman A Daoud
NPI 1487013512
$12,892.47
in general payments reported to CMS, 2019-2025
59 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,242 · 2021: $1,254 · 2022: $1,719 · 2023: $2,144 · 2024: $3,133 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,326 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,325.72 |
| Education | $192.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,716.68 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Supernus Pharmaceuticals, INC. | $1,228.60 | 2019-2024 | Qelbree |
| Pfizer INC. | $978.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $754.74 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $477.36 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $336.86 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $314.62 | 2019-2025 | Rexulti, Vyepti |
| Allergan, INC. | $275.73 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $261.08 | 2019-2025 | Crexont, Rytary |
| Biogen, INC. | $237.16 | 2019-2025 | Tysabri, Spinraza, Vumerity |
| Emd Serono, INC. | $231.38 | 2020-2025 | |
| Abbott Laboratories | $231.26 | 2022-2025 | Infinity, Proclaim |
| Genzyme Corporation | $217.82 | 2019-2022 | |
| Ucb, INC. | $211.74 | 2019-2025 | Briviact, Rystiggo |
| Upsher-Smith Laboratories LLC | $211.24 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.